ArticleBlood neoplasia2025

Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Ramsay Hafer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.